Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Olmesartan medoxomil.

Gregory T Warner1, Blair Jarvis

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 22, 2002
PubMed
Summary

Olmesartan medoxomil effectively lowers blood pressure by blocking angiotensin II receptors. Clinical trials show it is superior to placebo and comparable or superior to other antihypertensives like atenolol, captopril, losartan, valsartan, and irbesartan.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyberball: a program for use in research on interpersonal ostracism and acceptance.

Behavior research methods·2006
Same author

Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.

Treatments in endocrinology·2005
Same author

Micafungin.

Drugs·2004
Same author

Spotlight on ramipril in the prevention of cardiovascular outcomes.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2004
Same author

Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2004
Same author

Carvedilol: a review of its use in chronic heart failure.

Drugs·2003

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Trials

Background:

  • Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist.
  • It selectively inhibits the type 1 angiotensin II receptor, crucial for cardiovascular regulation.

Purpose of the Study:

  • To evaluate the efficacy and safety of olmesartan medoxomil in managing hypertension.
  • To compare its effectiveness against placebo and other antihypertensive agents.

Main Methods:

  • Randomized controlled trials and dose titration studies were conducted.
  • Comparisons included placebo, atenolol, captopril, losartan, valsartan, and irbesartan.
  • Pharmacokinetic interactions and adverse events were assessed.

Main Results:

  • Olmesartan medoxomil demonstrated significant superiority over placebo in reducing diastolic blood pressure (DBP).
  • It was at least as effective as atenolol and more effective than captopril, losartan, valsartan, and irbesartan in lowering DBP.
  • Superiority was also observed in reducing 24-hour ambulatory systolic blood pressure compared to losartan and valsartan.
  • No clinically significant pharmacokinetic interactions were noted with digoxin, warfarin, or antacids.
  • Adverse events were infrequent and similar to placebo, with dizziness being the most common, comparable to other ARBs.

Conclusions:

  • Olmesartan medoxomil is a highly effective antihypertensive agent.
  • Its efficacy and safety profile support its use in managing mild to moderate hypertension.

Related Experiment Videos